About LabCentral

In 2022, alongside out partner organization, LabCentral was the recipient of the Prix Galien Award, a prestigious award often regarded as the “Nobel Prize in the life sciences industry in the category, "Incubators, Accelerators and Equity".

28,000 sq. ft. just wasn't enough, and in 2017 we took over the second and third floors of our space at 700 Main Street, expanding our footprint to 75,000 sq.ft. In partnership with New England Biolabs, the LabCentral Learning Lab was also founded, providing dedicated space for STEM education and teacher training, laying the foundation for exciting opportunities to come.

As our companies grew, so did we, and with support from Pfizer we opened our second location at 610 Main Street to house to early- to mid-stage companies, with room to accommodate ~175 scientists and entrepreneurs.

In partnership with 53 industry sponsors, in our first five years LabCentral supported the development of 109 high-potential companies, and the creation of 1,922 new jobs, with billions invested into the Massachusetts economy as a result.

2020 brought into stark relief the breadth of the challenges we face in human health. LabCentral companies responded with urgency to the pandemic, in many cases pivoting their programs to develop novel solutions for rapid testing, vaccine development, and therapeutics. Our team responded in turn to keep the labs open and functional throughout the year, with zero days of lapsed service, so that our resident companies were able to continue to make advances in their work.

2020 was also a year of overwhelming social change, prompting a renewed focus on the human element behind the work we all do. In 2020, we formalized the creation of our Community Development and Social Impact functions to maintain the authenticity and vibrancy of our network, as well as our DEIB committee to continue growing, learning, and building better systems for a more equitable future.

From the foundation set forth by the LabCental Learning Lab, LabCentral Ignite was created to address systemic racial, gender and other underrepresentation in talent across the life sciences and the biotech industry. Ignite connects underrepresented students and innovators to academic, technical skills-building, mentoring, job placement, and board and leadership preparation opportunities that fuel biotech diversity and transform careers.

By 2021, LabCentral had enabled the testing of 80 novel technologies in the clinic. With an average duration of ~4 years from company start-date to the inital dosing of participants, we look to these clinical trials as representing not only our commitment to supporting innovators but also a ray of hope for the patients and families that one day may benefit from their success.